October 30 edition — delayed release on November 1. References to today and Friday in the audio refer to October 30.Acumen ends sabirnetug after a Phase 2 Alzheimer's trial lowered amyloid but missed on cognition and function, and Inovio's Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) won accelerated approval for adult recurrent respiratory papillomatosis, with benefit yet to be verified. Sun Pharma's Ilumya (tildrakizumab-asmn) is approved for active psoriatic arthritis, Agios' mitapivat sickle cell action date moved to February 1, 2027, and NRx says FDA approved its generic preservative-free ketamine. Dren Bio raised $350 million for dibotatug, and Setara $90 million for STAR-0871 in CMT2C. Regeneron's Eylea (aflibercept) and Sanofi's Dupixent (dupilumab) quarters and Nxera's operating-profit swing close it out.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →